Activation of the innate immune system in atherosclerotic disease

Current Pharmaceutical Design

Volumn 13, Issue 10, 2007, Pages 983-994

  Nijhuis, M M Oude ^a,b   van Keulen, J K ^a,b   Pasterkamp, G ^a   Quax, P H ^c   de Kleijn, D P V ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^c TNO   (Netherlands)

Author keywords

Atherogenesis; Infection; Inflammation; Innate immunity; Toll like receptors

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; E 5331; E 5531; E 5564; ERITORAN; LIGAND; LIPID A DERIVATIVE; LIPOPOLYSACCHARIDE ANTAGONIST; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; OXIDIZED LOW DENSITY LIPOPROTEIN; PLACEBO; RECEPTOR BLOCKING AGENT; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; VACCINE;

ANTIGEN RECOGNITION; ATHEROGENESIS; ATHEROSCLEROSIS; CLINICAL TRIAL; DISEASE COURSE; DRUG MEGADOSE; DRUG TARGETING; GENETIC POLYMORPHISM; HUMAN; INNATE IMMUNITY; KNOCKOUT MOUSE; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; VACCINATION;

ANIMALS; ATHEROSCLEROSIS; COMMUNICABLE DISEASES; HUMANS; IMMUNITY, NATURAL; IMMUNOTHERAPY; INFLAMMATION; LIGANDS; LIPOPOLYSACCHARIDES; LIPOPROTEINS; PEPTIDOGLYCAN; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS; VACCINES;

EID: 34247866518     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207780487593     Document Type: Review

References (130)

1. Malek AM, Alper SL, Izumo S. Hemodynamic shear stress and its role in atherosclerosis. JAMA 1999; 282: 2035-42.
2. Strong JP, Malcom GT, McMahan CA, Tracy RE, Newman WP, III, Herderick EE, et al. Prevalence and extent of atherosclerosis in adolescents and young adults: Implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. JAMA 1999; 281: 727-35.
3. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21: 1876-90.
4. Hansson GK, Libby P, Schonbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002; 91: 281-91.
5. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997; 272: 20963-6.
6. Camejo G, Hurt-Camejo E, Wiklund O, Bondjers G. Association of apo B lipoproteins with arterial proteoglycans: Pathological significance and molecular basis. Atherosclerosis 1998; 139: 205-22.
7. Williams KJ, Tabas I. The response-to-retention hypothesis of atherogenesis reinforced. Curr Opin Lipidol 1998; 9: 471-4.
8. Beekhuizen H, van Furth R. Monocyte adherence to human vascular endothelium. J Leukoc Biol 1993; 54: 363-78.
9. Jang Y, Lincoff AM, Plow EF, Topol EJ. Cell adhesion molecules in coronary artery disease. J Am Coll Cardiol 1994; 24: 1591-601.
10. McEver RP. Selectins. Curr Opin Immunol 1994; 6: 75-84.
11. Moore KL, Patel KD, Bruehl RE, Li F, Johnson DA, Lichenstein HS, et al. P-selectin glycoprotein ligand-1 mediates rolling of human neutrophils on P-selectin. J Cell Biol 1995; 128: 661-71.
12. Asa D, Raycroft L, Ma L, Aeed PA, Kaytes PS, Elhammer AP, et al. The P-selectin glycoprotein ligand functions as a common human leukocyte ligand for P- and E-selectins. J Biol Chem 1995; 270: 11662-70.
13. Dong ZM, Chapman SM, Brown AA, Frenette PS, Hynes RO, Wagner DD. The combined role of P- and E-selectins in atherosclerosis. J Clin Invest 1998; 102: 145-52.
14. Chuluyan HE, Issekutz AC. VLA-4 integrin can mediate CD11/ CD18-independent transendothelial migration of human monocytes. J Clin Invest 1993; 92: 2768-77.
15. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm. Cell 1994; 76: 301-14.
16. Muller WA, Randolph GJ. Migration of leukocytes across endothelium and beyond: Molecules involved in the transmigration and fate of monocytes. J Leukoc Biol 1999; 66: 698-704.
17. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340: 115-26.
18. Lusis AJ. Atherosclerosis. Nature 2000; 407: 233-41.
19. Nicoletti A, Caligiuri G, Tornberg I, Kodama T, Stemme S, Hansson GK. The macrophage scavenger receptor type A directs modified proteins to antigen presentation. Eur J Immunol 1999; 29: 512-21.
20. Hashimoto C, Hudson KL, Anderson KV. The Toll gene of Drosophila, required for dorsal-ventral embryonic polarity, appears to encode a transmembrane protein. Cell 1988; 52: 269-79.
21. Medzhitov R, Preston-Hurlburt P, Janeway CA, Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997; 388: 394-7.
22. Rock FL, Hardiman G, Timans JC, Kastelein RA, Bazan JF. A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci USA 1998; 95: 588-93.
23. Abreu MT, Fukata M, Arditi M. TLR signaling in the gut in health and disease. J Immunol 2005; 174: 4453-60.
24. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003; 21: 335-76.
25. Abreu MT, Arditi M. Innate immunity and toll-like receptors: Clinical implications of basic science research. J Pediatr 2004; 144: 421-9.
26. Takeuchi O, Kawai T, Sanjo H, Copeland NG, Gilbert DJ, Jenkins NA, et al. TLR6: A novel member of an expanding toll-like receptor family. Gene 1999; 231: 59-65.
27. Chuang TH, Ulevitch RJ. Cloning and characterization of a subfamily of human toll-like receptors: HTLR7, hTLR8 and hTLR9. Eur Cytokine Netw 2000; 11: 372-8.
28. Du X, Poltorak A, Wei Y, Beutler B. Three novel mammalian tolllike receptors: Gene structure, expression, and evolution. Eur Cytokine Netw 2000; 11: 362-71.
29. Takeuchi O, Hoshino K, Kawai T, Sanjo H, Takada H, Ogawa T, et al. Differential roles of TLR2 and TLR4 in recognition of gramnegative and gram-positive bacterial cell wall components. Immunity 1999; 11: 443-51.
30. Takeuchi O, Sato S, Horiuchi T, Hoshino K, Takeda K, Dong Z, et al. Cutting edge: Role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J Immunol 2002; 169: 10-4.
31. Takeuchi O, Kawai T, Muhlradt PF, Morr M, Radolf JD, Zychlinsky A, et al. Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int Immunol 2001; 13: 933-40.
32. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001; 413: 732-8.
33. Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001; 410: 1099-103.
34. Lund JM, Alexopoulou L, Sato A, Karow M, Adams NC, Gale NW, et al. Recognition of single-stranded RNA viruses by Tolllike receptor 7. Proc Natl Acad Sci USA 2004; 101: 5598-603.
35. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002; 3: 196-200.
36. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408: 740-5.
37. Jurk M, Heil F, Vollmer J, Schetter C, Krieg AM, Wagner H, et al. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol 2002; 3: 499.
38. Akira S. Toll-like receptor signaling. J Biol Chem 2003; 278: 38105-8
39. Takeda K, Akira S. TLR signaling pathways. Semin Immunol 2004; 16: 3-9.
40. Akira S, Takeda K. Functions of toll-like receptors: Lessons from KO mice. C R Biol 2004; 327: 581-9.
41. Palsson-McDermott EM, O'Neill LA. Signal transduction by the lipopolysaccharide receptor, Toll-like receptor-4. Immunology 2004; 113: 153-62.
42. Bannerman DD, Goldblum SE. Direct effects of endotoxin on the endothelium: Barrier function and injury. Lab Invest 1999; 79: 1181-99.
43. Zeuke S, Ulmer AJ, Kusumoto S, Katus HA, Heine H. TLR4-mediated inflammatory activation of human coronary artery endothelial cells by LPS. Cardiovasc Res 2002; 56: 126-34.
44. Moller AS, Ovstebo R, Westvik AB, Joo GB, Haug KB, Kierulf P. Effects of bacterial cell wall components (PAMPs) on the expression of monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein-1alpha (MIP-1alpha) and the chemokine receptor CCR2 by purified human blood monocytes. J Endotoxin Res 2003; 9: 349-60.
45. Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 1998; 2: 275-81.
46. Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998; 394: 894-7.
47. Vink A, Schoneveld AH, van der Meer JJ, van Middelaar BJ, Sluijter JP, Smeets MB, et al. In vivo evidence for a role of toll-like receptor 4 in the development of intimal lesions. Circulation 2002; 106: 1985-90.
48. Hollestelle SC, De Vries MR, Van Keulen JK, Schoneveld AH, Vink A, Strijder CF, et al. Toll-like receptor 4 is involved in outward arterial remodeling. Circulation 2004; 109: 393-8.
49. Lehr HA, Sagban TA, Ihling C, Zahringer U, Hungerer KD, Blumrich M, et al. Immunopathogenesis of atherosclerosis: Endotoxin accelerates atherosclerosis in rabbits on hypercholesterolemic diet. Circulation 2001; 104: 914-20.
50. Ostos MA, Recalde D, Zakin MM, Scott-Algara D. Implication of natural killer T cells in atherosclerosis development during a LPSinduced chronic inflammation. FEBS Lett 2002; 519: 23-9.
51. Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA 2004; 101: 10679-84.
52. Bjorkbacka H, Kunjathoor VV, Moore KJ, Koehn S, Ordija CM, Lee MA, et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med 2004; 10: 416-21.
53. Wright SD, Burton C, Hernandez M, Hassing H, Montenegro J, Mundt S, et al. Infectious agents are not necessary for murine atherogenesis. J Exp Med 2000; 191: 1437-42.
54. Schoneveld AH, Oude Nijhuis MM, van Middelaar B, Laman JD, de Kleijn DP, Pasterkamp G. Toll-like receptor 2 stimulation induces intimal hyperplasia and atherosclerotic lesion development. Cardiovasc Res 2005; 66: 162-9.
55. Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ. Expression of toll-like receptors in human atherosclerotic lesions: A possible pathway for plaque activation. Circulation 2002; 105: 1158-61.
56. Xu XH, Shah PK, Faure E, Equils O, Thomas L, Fishbein MC, et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 2001; 104: 3103-8.
57. Laman JD, Schoneveld AH, Moll FL, van Meurs M, Pasterkamp G. Significance of peptidoglycan, a proinflammatory bacterial antigen in atherosclerotic arteries and its association with vulnerable plaques. Am J Cardiol 2002; 90: 119-23.
58. Nijhuis MM, van der Graaf Y, Melief MJ, Schoneveld AH, de Kleijn DP, Laman JD, et al. IgM antibody level against proinflammatory bacterial peptidoglycan is inversely correlated with extent of atherosclerotic disease. Atherosclerosis 2004; 173: 245-51.
59. Dziarski R, Gupta D. Staphylococcus aureus peptidoglycan is a toll-like receptor 2 activator: A reevaluation. Infect Immun 2005; 73: 5212-6.
60. Travassos LH, Girardin SE, Philpott DJ, Blanot D, Nahori MA, Werts C, et al. Toll-like receptor 2-dependent bacterial sensing does not occur via peptidoglycan recognition. EMBO Rep 2004; 5: 1000-6.
61. Girardin SE, Boneca IG, Viala J, Chamaillard M, Labigne A, Thomas G, et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 2003; 278: 8869-72.
62. Girardin SE, Boneca IG, Carneiro LA, Antignac A, Jehanno M, Viala J, et al. Nod1 detects a unique muropeptide from gramnegative bacterial peptidoglycan. Science 2003; 300: 1584-7.
63. Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000; 25: 187-91.
64. Kiechl S, Lorenz E, Reindl M, Wiedermann CJ, Oberhollenzer F, Bonora E, et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002; 347: 185-92.
65. Ameziane N, Beillat T, Verpillat P, Chollet-Martin S, Aumont MC, Seknadji P, et al. Association of the Toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events. Arterioscler Thromb Vasc Biol 2003; 23: E61-4.
66. Edfeldt K, Bennet AM, Eriksson P, Frostegard J, Wiman B, Hamsten A, et al. Association of hypo-responsive toll-like receptor 4 variants with risk of myocardial infarction. Eur Heart J 2004; 25: 1447-53.
67. Zee RY, Hegener HH, Gould J, Ridker PM. Toll-like receptor 4 Asp299Gly gene polymorphism and risk of atherothrombosis. Stroke 2005; 36: 154-7.
68. Netea MG, Hijmans A, van Wissen S, Smilde TJ, Trip MD, Kullberg BJ, et al. Toll-like receptor-4 Asp299Gly polymorphism does not influence progression of atherosclerosis in patients with familial hypercholesterolaemia. Eur J Clin Invest 2004; 34: 94-9.
69. Yang IA, Holloway JW, Ye S. TLR4 Asp299Gly polymorphism is not associated with coronary artery stenosis. Atherosclerosis 2003; 170: 187-90.
70. Ohashi K, Burkart V, Flohe S, Kolb H. Cutting edge: Heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol 2000; 164: 558-61.
71. Okamura Y, Watari M, Jerud ES, Young DW, Ishizaka ST, Rose J, et al. The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 2001; 276: 10229-33.
72. Termeer C, Benedix F, Sleeman J, Fieber C, Voith U, Ahrens T, et al. Oligosaccharides of Hyaluronan activate dendritic cells via tolllike receptor 4. J Exp Med 2002; 195: 99-111.
73. Schaefer L, Babelova A, Kiss E, Hausser HJ, Baliova M, Krzyzankova M, et al. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest 2005; 115: 2223-33.
74. Shiozawa K, Hino K, Shiozawa S. Alternatively spliced EDAcontaining fibronectin in synovial fluid as a predictor of rheumatoid joint destruction. Rheumatology (Oxford) 2001; 40: 739-42.
75. Adamia S, Maxwell CA, Pilarski LM. Hyaluronan and hyaluronan synthases: potential therapeutic targets in cancer. Curr Drug Targets Cardiovasc Haematol Disord 2005; 5: 3-14.
76. Venkatesan N, Ebihara T, Roughley PJ, Ludwig MS. Alterations in large and small proteoglycans in bleomycin-induced pulmonary fibrosis in rats. Am J Respir Crit Care Med 2000; 161: 2066-73.
77. Sime PJ, Samstrand B, Xing Z, Graham F, Fisher L, Gauldie J. Adenovirus-mediated gene transfer of the proteoglycan biglycan induces fibroblastic responses in the lung. Chest 1997; 111: 137S.
78. Tan MH, Sun Z, Opitz SL, Schmidt TE, Peters JH, George EL. Deletion of the alternatively spliced fibronectin EIIIA domain in mice reduces atherosclerosis. Blood 2004; 104: 11-8.
79. Saito S, Yamaji N, Yasunaga K, Saito T, Matsumoto S, Katoh M, et al. The fibronectin extra domain A activates matrix metalloproteinase gene expression by an interleukin-1-dependent mechanism. J Biol Chem 1999; 274: 30756-63.
80. Kunjathoor VV, Chiu DS, O'Brien KD, LeBoeuf RC. Accumulation of biglycan and perlecan, but not versican, in lesions of murine models of atherosclerosis. Arterioscler Thromb Vasc Biol 2002; 22: 462-8.
81. Riessen R, Isner JM, Blessing E, Loushin C, Nikol S, Wight TN. Regional differences in the distribution of the proteoglycans biglycan and decorin in the extracellular matrix of atherosclerotic and restenotic human coronary arteries. Am J Pathol 1994; 144: 962-74.
82. O'Brien KD, Olin KL, Alpers CE, Chiu W, Ferguson M, Hudkins K, et al. Comparison of apolipoprotein and proteoglycan deposits in human coronary atherosclerotic plaques: Colocalization of biglycan with apolipoproteins. Circulation 1998; 98: 519-27.
83. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: Is there a link? Lancet 1997; 350: 430-6.
84. Ridker PM. Inflammation, infection, and cardiovascular risk: How good is the clinical evidence? Circulation 1998; 97: 1671-4.
85. Zhou YF, Leon MB, Waclawiw MA, Popma JJ, Yu ZX, Finkel T, et al. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med 1996; 335: 624-30
86. Sorlie PD, Nieto FJ, Adam E, Folsom AR, Shahar E, Massing M. A prospective study of cytomegalovirus, herpes simplex virus 1, and coronary heart disease: The atherosclerosis risk in communities (ARIC) study. Arch Intern Med 2000; 160: 2027-32.
87. Ridker PM, Hennekens CH, Stampfer MJ, Wang F. Prospective study of herpes simplex virus, cytomegalovirus, and the risk of future myocardial infarction and stroke. Circulation 1998; 98: 2796-9.
88. Ameriso SF, Fridman EA, Leiguarda RC, Sevlever GE. Detection of Helicobacter pylori in human carotid atherosclerotic plaques. Stroke 2001; 32: 385-91.
89. Pieniazek P, Karczewska E, Duda A, Tracz W, Pasowicz M, Konturek SJ. Association of Helicobacter pylori infection with coronary heart disease. J Physiol Pharmacol 1999; 50: 743-51.
90. Tsai CJ, Huang TY. Relation of Helicobacter pylori infection and angiographically demonstrated coronary artery disease. Dig Dis Sci 2000; 45: 1227-32.
91. Menge H, Lang A, Brosius B, Hopert R, Lollgen H. Helicobacter pylori and coronary heart diseases--hypotheses and facts. Z Gastroenterol 2000; 38: 315-23.
92. Danesh J, Peto R. Risk factors for coronary heart disease and infection with Helicobacter pylori: Meta-analysis of 18 studies. BMJ 1998; 316: 1130-2.
93. Espinola-Klein C, Rupprecht HJ, Blankenberg S, Bickel C, Kopp H, Rippin G, et al. Impact of infectious burden on extent and longterm prognosis of atherosclerosis. Circulation 2002; 105: 15-21.
94. Rupprecht HJ, Blankenberg S, Bickel C, Rippin G, Hafner G, Prellwitz W, et al. Impact of viral and bacterial infectious burden on long-term prognosis in patients with coronary artery disease. Circulation 2001; 104: 25-31.
95. Gibbs RG, Carey N, Davies AH. Chlamydia pneumoniae and vascular disease. Br J Surg 1998; 85: 1191-7.
96. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, et al. Chlamydia pneumoniae IgG titres and coronary heart disease: prospective study and meta-analysis. BMJ 2000; 321: 208-13.
97. Bloemenkamp DG, Mali WP, Visseren FL, van der GY. Metaanalysis of sero-epidemiologic studies of the relation between Chlamydia pneumoniae and atherosclerosis: Does study design influence results? Am Heart J 2003; 145: 409-17.
98. Grayston JT. Antibiotic treatment of atherosclerotic cardiovascular disease. Circulation 2003; 107: 1228-30.
99. O'Connor CM, Dunne MW, Pfeffer MA, Muhlestein JB, Yao L, Gupta S, et al. Azithromycin for the secondary prevention of coronary heart disease evenAs: The WIZARD study: a randomized controlled trial. JAMA 2003; 290: 1459-66.
100. Jackson LA. Description and status of the azithromycin and coronary events study (ACES). J Infect Dis 2000; 181(Suppl 3): S579-81.
101. Pokrovskaia EV. Final confirmation of inefficiency of antibiotics in secondary prevention of coronary heart disease. Results of PROVE IT (gatifloxacin trial) and ACES. Kardiologiia 2004; 44: 82-3.
102. Gieffers J, Fullgraf H, Jahn J, Klinger M, Dalhoff K, Katus HA, et al. Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation 2001; 103: 351-6.
103. Andraws R, Berger JS, Brown DL. Effects of antibiotic therapy on outcomes of patients with coronary artery disease: A meta-analysis of randomized controlled trials. JAMA 2005; 293: 2641-7.
104. Rhee SH, Hwang D. Murine TOLL-like receptor 4 confers lipopolysaccharide responsiveness as determined by activation of NF kappa B and expression of the inducible cyclooxygenase. J Biol Chem 2000; 275: 34035-40.
105. Takada H, Kotani S. Structural requirements of lipid A for endotoxicity and other biological activities. Crit Rev Microbiol 1989; 16: 477-523
106. Rose JR, Mullarkey MA, Christ WJ, Hawkins LD, Lynn M, Kishi Y, et al. Consequences of interaction of a lipophilic endotoxin antagonist with plasma lipoproteins. Antimicrob Agents Chemother 2000; 44: 504-10.
107. Mullarkey M, Rose JR, Bristol J, Kawata T, Kimura A, Kobayashi S, et al. Inhibition of endotoxin response by e5564, a novel Tolllike receptor 4-directed endotoxin antagonist. J Pharmacol Exp Ther 2003; 304: 1093-102.
108. Wong YN, Rossignol D, Rose JR, Kao R, Carter A, Lynn M. Safety, pharmacokinetics, and pharmacodynamics of E5564, a lipid A antagonist, during an ascending single-dose clinical study. J Clin Pharmacol 2003; 43: 735-42.
109. Rossignol DP, Wasan KM, Choo E, Yau E, Wong N, Rose J, et al. Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of eritoran (E5564) during continuous intravenous infusion into healthy volunteers. Antimicrob Agents Chemother 2004; 48: 3233-40.
110. Wick G, Knoflach M, Xu Q. Autoimmune and inflammatory mechanisms in atherosclerosis. Annu Rev Immunol 2004; 22: 361-403.
111. von Herrath MG. Vaccination to prevent type 1 diabetes. Expert Rev Vaccines 2002; 1: 25-8.
112. George J, Afek A, Gilburd B, Levkovitz H, Shaish A, Goldberg I, et al. Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis. Atherosclerosis 1998; 138: 147-52.
113. Ameli S, Hultgardh-Nilsson A, Regnstrom J, Calara F, Yano J, Cercek B, et al. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 1996; 16: 1074-9.
114. Palinski W, Miller E, Witztum JL. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci USA 1995; 92: 821-5.
115. Salonen JT, Yla-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992; 339: 883-7.
116. Wu R, Nityanand S, Berglund L, Lithell H, Holm G, Lefvert AK. Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction. Arterioscler Thromb Vasc Biol 1997; 17: 3159-63.
117. Shaw PX, Horkko S, Tsimikas S, Chang MK, Palinski W, Silverman GJ, et al. Human-derived anti-oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo. Arterioscler Thromb Vasc Biol 2001; 21: 1333-9.
118. Robinson DS, O'Garra A. Further checkpoints in Th1 development. Immunity 2002; 16: 755-8.
119. Ito T, Amakawa R, Kaisho T, Hemmi H, Tajima K, Uehira K, et al. Interferon-alpha and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets. J Exp Med 2002; 195: 1507-12.
120. Su SB, Silver PB, Grajewski RS, Agarwal RK, Tang J, Chan CC, et al. Essential role of the MyD88 pathway, but nonessential roles of TLRs 2, 4, and 9, in the adjuvant effect promoting Th1-mediated autoimmunity. J Immunol 2005; 175: 6303-10.
121. Re F, Strominger JL. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J Biol Chem 2001; 276: 37692-9.
122. Lauw FN, ten Hove T, Dekkers PE, de Jonge E, van Deventer SJ, van Der PT. Reduced Th1, but not Th2, cytokine production by lymphocytes after in vivo exposure of healthy subjects to endotoxin. Infect Immun 2000; 68: 1014-8.
123. Cochran JR, Khan AM, Elidemir O, Xue H, Cua B, Fullmer J, et al. Influence of lipopolysaccharide exposure on airway function and allergic responses in developing mice. Pediatr Pulmonol 2002; 34: 267-77.
124. Eisenbarth SC, Piggott DA, Huleatt JW, Visintin I, Herrick CA, Bottomly K. Lipopolysaccharide-enhanced, toll-like receptor 4-dependent T helper cell type 2 responses to inhaled antigen. J Exp Med 2002; 196: 1645-51.
125. Emeson EE, Shen ML, Bell CG, Qureshi A. Inhibition of atherosclerosis in CD4 T-cell-ablated and nude (nu/nu) C57BL/6 hyperlipidemic mice. Am J Pathol 1996; 149: 675-85.
126. Zhou X, Nicoletti A, Elhage R, Hansson GK. Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation 2000; 102: 2919-22.
127. Zhou X, Paulsson G, Stemme S, Hansson GK. Hypercholesterolemia is associated with a T helper (Th) 1/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice. J Clin Invest 1998; 101: 1717-25.
128. Ishii KJ, Uematsu S, Akira S. 'Toll' gates for future immunotherapy. Curr Pharm Des 2006; 12(32): 4135-42.
129. Nochi T, Kiyono H. Innate immunity in the mucosal immune system. Curr Pharm Des 2006; 12(32): 4203-13.
130. Stoll LL, Denning GM, Weintraub NL. Endotoxin, TLR4 signaling and vascular inflammation: Potential therapeutic targets in cardiovascular disease. Curr Pharm Des 2006; 12(32): 4229-45.